Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
about
Recent advances in understanding and treating vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesAltered B cell signalling in autoimmunity.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabRituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitisLow immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.Predictors of relapses in ANCA-associated small vessel vasculitis with kidney involvement.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?Biologic agents in the treatment of glomerulonephritides.Late-onset neutropenia after rituximab in ANCA-associated vasculitis.Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Clinical trials. Rituximab for maintenance of remission in AAV.The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?Understanding the role of rituximab in ANCA GN: regressing toward the meanThe European Vasculitis Society 2016 Meeting Report.Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomen[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
P2860
Q26747046-2E90DCDD-CC3D-455E-98DF-E993FFA025D8Q26776308-EDCD2648-3BE0-4179-86C2-0DB054EF69BBQ33924642-73D39A2D-BCA1-436C-8B51-8EC3D3D2E8DBQ35065425-4A5BF9CA-67A1-461C-8311-07FE77A3DBE9Q35662018-5B983EF0-5381-4B59-8A1B-E2FC5A55D944Q35759180-CD50E650-0387-4673-B16A-27C7101BAC89Q35887318-0396FF79-3D93-44FB-9D40-2B3441061FB7Q35946429-EF934660-178B-464E-9763-13F97EA0784DQ36265388-A49CFB2B-5CAD-4789-8F5E-53930E5A67C6Q36744892-FAAB0316-1FFA-45B2-9DB3-0276625FEC17Q37031689-FC7E3088-9D2A-460D-8B18-303D65A52CFEQ37686029-04E79C43-4F25-44C5-887C-3AC7B90F43D2Q38327634-AB510721-C373-4F10-B7C7-BBDC9FB6108DQ38514894-E124BD8C-D7F4-47D1-AA3D-A55127AB732CQ39944154-78DE9D2C-4AAE-4642-944F-AF3820F32038Q40393067-3D7F6F52-25CF-48DC-8757-4C697BD0E764Q41124267-7032318E-B813-419A-9F34-3977A33006C8Q41208157-DB94E7DC-C052-45B2-AD92-A89C9BAF059CQ41563712-B906167E-9EC3-4AE6-A3F5-225586AABF9CQ41592598-FA8E27A5-BED3-45A8-BA86-B2FD3C3DB41FQ42380186-78D89044-8332-4AAA-824E-DEF6CDC71C5BQ42563782-70BBDD08-3E70-4ADB-A69F-55E4A70869F3Q47107377-BFAE9833-85A7-46CA-B2CD-ED45C94BB11AQ47163408-649B94E1-4251-403C-A34B-1BD4FCA67AFBQ50076914-637923A3-8AC6-47F6-8CC7-BEEA713C2091Q55191066-85AF1A11-7CC6-47D3-8EE1-9F0A4A51BAF3
P2860
Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@en
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@nl
type
label
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@en
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@nl
prefLabel
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@en
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@nl
P2093
P2860
P356
P1476
Long-term maintenance therapy ...... patients with ANCA vasculitis.
@en
P2093
Andrew P Murphy
Eugene P Rhee
Frank B Cortazar
John L Niles
Julia Wenger
Karen A Laliberte
William F Pendergraft
P2860
P304
P356
10.2215/CJN.07340713
P577
2014-03-13T00:00:00Z